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Background: Lactuca sativa (garden lettuce) is a popular salad herb. It has been in use in folk 
medicine since ancient times as both an appetite stimulant and as an aid to sleep. L. sativa seed 
oil (Sedan®) has demonstrated a pronounced sedative effect and potentiated the hypnotic effect 
of barbiturates in animal models. It also exhibited significant analgesic and anti-inflammatory 
activities. In this study, we evaluated the sedative and hypnotic effects of L. sativa in patients 
suffering from insomnia.
Methods: Sixty patients suffering from insomnia with or without anxiety were randomized 
to receive capsules containing L. sativa seed oil 1000 mg (n = 30) or placebo (n = 30). All 
patients were asked to complete a verbal questionnaire before the start of the trial and 1 week 
after starting treatment.
Results: Improvements in the modified State-Trait Anxiety Inventory and the Sleep rating 
scale scores were significantly greater in patients receiving L. sativa seed oil compared with 
those on placebo (P , 0.05). No side effects were found to be attributable to L. sativa seed oil 
at the given dosage.
Conclusion: L. sativa seed oil was found to be a useful sleeping aid and may be a hazard-free 
line of treatment, especially in geriatric patients suffering from mild-to-moderate forms of 
anxiety and sleeping difficulties.
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Introduction
Sleep loss and sleep disorders are among the most common health problems, but are 
frequently overlooked. It is estimated that about one-third of people in the   general 
  population suffer from a chronic disorder of sleep and wakefulness.1 Insomnia 
is a   subjective complaint that sleep is difficult to initiate or maintain, or that it is 
nonrefreshing or of poor quality and quantity.2
Insomnia affects approximately 20%–40% of older adults at least a few nights per 
month.3,4 It is an important concern in elderly patients, not only because it is common, 
but also because it can cause multiple daytime impairments, such as difficulty sustaining 
attention or alertness, a slowed response time, impaired memory and concentration, and 
decreased performance. Insomnia is also associated with a shortened lifespan because 
of an increased risk of heart disease, stroke, cancer, and suicide.5,6
Insomnia is mostly treated with benzodiazepine and nonbenzodiazepine hypnotic 
drugs, which potentiate the central nervous system suppressant activity of gamma 
aminobutyric acid A receptors in the brain. However, residual daytime effects, 
development of dependence, and withdrawal symptoms associated with most hypnotic 
drugs are of considerable concern in public health.7International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Lactuca sativa (garden lettuce), a member of the 
  Compositae family, is a very popular salad herb in Egypt.8,9 
Its seed oil has been in use in folk medicine since ancient 
times as a sleeping aid, as well as to relieve pain and 
inflammation.10,11
A crude methanol/petroleum ether extract from 
L. sativa seeds has demonstrated a time-dependent and 
dose-dependent analgesic effect in a formalin test and also 
dose-dependent anti-inflammatory activity in a carrageenan 
model of inflammation.12
L. sativa seed oil (Sedan®, Pharco Pharmaceutical 
  Company, Alexandria, Egypt) is marketed as a soft gelatin 
capsule containing 1000 mg of the purified expressed oil. 
Gas liquid chromatography shows that the L. sativa seed oil 
capsule is comprised mainly of oleic acid (61.5%), stearic 
acid (20.4%), palmitic acid (9.7%), myristic acid (2.8%), 
  cis-palmitoleic (1.2%), behenic acid (0.5%), and lignoseric 
acid (0.3%), with B-sitosterol and B-amryn also present.
Despite its well-known safety over thousands of years 
of use, L. sativa seed oil has only recently been subjected to 
extensive pharmacological and toxicological investigation. 
It was found to have significant sedative, analgesic, and anti-
inflammatory activity in a murine model,13 and in the same 
study was shown to have significant anticonvulsant activity 
against convulsions induced by pentylenetetrazole and to 
potentiate the hypnotic effect of barbiturates. The oral LD50 
was found to be 19.75 mL/kg.13
The scientific data from this animal research in addition 
to the extensive anecdotal experience of successive gen-
erations of traditional Egyptian herbalists, prompted our 
research group, which has a special interest in traditional 
herbal medicines, to undertake a pilot clinical study to 
evaluate the sedative and hypnotic effects of L. sativa seed 
oil in patients complaining of sleeping difficulty with or 
without anxiety.
Methods
This was a prospective single-blind, randomized, placebo-con-
trolled trial performed in two outpatient clinics in Alexandria, 
one at the Mamorah Psychiatric Hospital and the other at the 
Green Clinical Research Center. Sixty consecutive patients 
presenting with insomnia or sleeping difficulty were recruited 
for the study after careful medical history-taking and a physical 
examination. Patients were included if they were aged over 18 
years and had a presenting complaint of insomnia, defined as 
frequently upset sleep quantity/quality or difficulty in initiat-
ing or sustaining a normal deep sleep pattern. Dementia of the 
Alzheimer’s type was not an exclusion criterion if the patient 
had a supportive partner/caregiver. Patients with concomitant 
organic or neuropsychiatric disease necessitating use of tran-
quilizers, sedatives, anticonvulsants, or psychotropic agents 
were excluded. Patients who were concomitantly receiving any 
other conventional or alternative medical intervention which 
might influence the study outcome, including all other herbal 
products, hypnotherapy, acupuncture, homeopathy, and yoga, 
were also excluded. Patients were asked not to use any of these 
concomitant interventions during the course of the study, 
and were excluded from the analysis if they did so. Critically 
ill patients with severe heart, renal, or liver   dysfunction 
were excluded, as were patients whose condition precluded 
verbal communication, unless they were accompanied by a 
supportive partner/caregiver. The protocol was approved by 
the local research ethical committee (IORG0006902 Green 
Clinic and Research Center IRB #1), and each subject signed 
a consent form.
The patients were randomized into two treatment groups. 
Group 1 (n = 30) received one Sedan capsule every night for 
1 week and Group 2 (n = 30) received a matching placebo. 
Randomization was done using a software-generated block 
randomization technique and the patients were blinded to 
their allocated drug. Double-blinding was not possible in 
this pilot study because the baseline examination, supply of 
medication, and final assessment were all carried out by the 
same investigator at each clinic.
Outcome measures
The effect of Sedan vs placebo on both the modified State-
Trait Anxiety Inventory (STAI) score14 and a sleeping 
difficulty score was assessed at the end of 1 week of treatment. 
The modified STAI scale comprises 20 questions, each of 
which is answered on a five-point scale, from 1 (nil) to 4 
(very much). The sleeping difficulty scale was a 10-item 
questionnaire based on the items of The Leeds Sleep Evaluation 
Questionnaire15 and assessed subjective patient estimates of 
and satisfaction with sleep quality using a three-point rating 
scale (0 = rare/nil, 1 = sometimes, and 2 = often). The higher 
the total score on both scales, the worse the patient’s insomnia 
was deemed to be. Both questionnaires were administered 
verbally at baseline and at the end of 1 week of treatment. 
Both instruments were translated into the Arabic language by 
the investigators and had been validated previously in patients 
with anxiety and insomnia treated at Mamorah Psychiatric 
Hospital (unpublished data). Clinical Global Impression of 
Change (CGI-C) scores were also recorded by the investigator 
at baseline after 1 week of treatment. The CGI-C is a seven-
item symptom rating scale (0 = not assessed, 1 = very much International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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improved, 2 = much improved, 3 = minimally improved, 4 = no 
change, 5 = minimally worse, 6 = much worse, 7 = very much 
worse).
statistical analysis
Data were analyzed using the computer software package 
SPSS (v 14; SPSS, Inc, Chicago, IL). Sample size was cal-
culated using SigmaStat® (v 3.5 for Windows; Systat Soft-
ware, Inc, Chicago, IL). The minimum sample size needed 
for each treatment group was calculated to be 23 subjects to 
detect a difference of 3.0 points in mean sleep scale scores 
with a standard deviation (SD) of 3.5, 80% power, and a 0.05 
two-tailed level of significance. A paired-samples t-test was 
done to compare the mean scores for each group before and 
after treatment. An independent-samples t-test was done to 
test for a significant difference between any improvements 
in mean score in each treatment group.
Multivariate analysis of covariance with treatment 
as the main independent factor and the study center as a 
controlling factor was used in full factorial model testing for 
main effects plus any possible interaction effects. Baseline 
pretreatment scores were used as covariates to control for 
initial group differences potentially affecting the dependent 
outcome variables, ie, any differences between baseline and 
posttreatment STAI and sleep scores, and their interaction. 
Parametric statistical methods were utilized after ascertaining 
the normality of distribution of the dependent variables by 
Kolmogorov–Smirnov goodness of fit test.
Results
Two patients from Group 1 and one from Group 2 withdrew 
from the study after randomization, and three patients in each 
group were lost to follow-up. One patient from Group 2 was 
not included in the statistical analysis as a result of recording 
errors made on the sleep scoring sheet. Twenty-five patients 
from each group were finally assessed, and their results 
were subjected to statistical analysis. The two groups were 
well matched for age, gender, and baseline sleep scores   
(see Table 1).
Cronbach’s alpha coefficients for the 20 items on the mod-
ified STAI scale and for the ten items of the sleeping difficulty 
scale were 0.835 and 0.764, respectively, indicating good 
reliability. There was a statistically significant improvement 
in mean scores for both the modified STAI and the sleep-
ing difficulty questionnaires in both groups after treatment 
(Tables 2 and 3). However, improvements in both the mean 
modified STAI score and mean sleep score were significantly 
greater in Group 1 than in Group 2 by independent-samples 
t-test (P , 0.05).
Multivariate analysis was undertaken using treatment 
allocation as the main independent factor and the study 
center as a controlling factor in a full factorial model, with 
baseline scores as covariates (Tables 4 and 5). Treatment 
allocation and baseline scores (covariates) had statistically 
significant effects on the outcome variables, while both the 
study center and its two-way interaction with treatment 
(group, center) did not. Univariate effects of the corrected 
model and the treatment groups adjusted for baseline severity 
on both the STAI and sleep score showed statistically 
significant differences, while the study center and its two-
way interaction with the groups did not.
Eighteen out of the 25 patients who completed the 
protocol (72%) in Group 1 rated their insomnia as “very 
much or much improved” on the CGIC scale, versus 5 (20%) 
in the control group (ie, 60% vs 16.7% respectively of the 30 
intention-to-treat patients) (risk ratio: 3.6; 95% confidence 
interval: 1.58–8.18).
Discussion
To our knowledge, this is the first published study of the 
effect of L. sativa seed oil on a sleeping disorder. We found 
that L. sativa seed oil significantly improved both STAI 
and sleep scores, with no apparent side effects at the dose 
strength used.
Being clinicians with a special interest in complementary 
alternative medicine, we undertook this pilot research on 
a pragmatic hypothesis-generating basis, rather than as a 
confirmatory or explanatory study, and hope that our findings 
will help pave the way for other investigators to join in the 
attempt to bridge the gap between alternative medicine 
and evidence-based medicine. This study has a number of 
limitations, including a small size, a short follow-up duration, 
and a single-blind design. The obvious reason for this is 
that, unlike patented new chemical entities with research 
funding from the pharmaceutical industry, quality research 
involving alternative medicines tends to suffer from financial 
and logistic constraints.
Table 1 Baseline characteristics of the study population
Characteristic L. sativa  
(n = 25)
Placebo  
(n = 25)
P-value
Age, years (mean ± sD) 62.5 ± 8.5 63.6 ± 7.8 0.636
Gender (M/F) 18/7 17/8 0.5
Mean total sTAI score 58 ± 8.6 57 ± 9.2 0.693
Mean total sleeping score 11.84 ± 6.2 12.08 ± 5.8 0.888
Abbreviations: M, male; F, female; sTAI, state-Trait Anxiety Inventory; sD, standard 
deviation.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Paired-samples descriptive statistics for sTAI and sleep scores
Treatment group Paired variables Mean n SD
experimental Pair 1 Total sTAI score after treatment 45.52 25 12.65
Total sTAI score before treatment 58.08 25 10.64
Pair 2 Total sleep score after treatment 7.4 25 3.56
Total sleep score before treatment 11.84 25 4.04
Placebo Pair 1 Total sTAI score after treatment 51.52 25 10.77
Total sTAI score before treatment 57 25 9.33
Pair 2 Total sleep score after treatment 10.16 25 3.51
Total sleep score before treatment 12.08 25 3.58
Abbreviations: sTAI, state-Trait Anxiety Inventory; sD, standard deviation.
Table 3 Paired-samples t-test for sTAI and sleep scores
Treatment group Variable  
pairs
Paired differences 95% CI t df P-value
Mean SD Lower Upper
experimental Pair 1 -12.56 12.23 -17.61 -7.51 -5.13 24 0.00
Pair 2 -4.44 4.56 -6.32 -2.56 -4.87 24 0.00
Placebo Pair 1 -5.48 10.31 -9.74 -1.22 -2.66 24 0.01
Pair 2 -1.92 4.48 -3.77 -0.07 -2.14 24 0.04
Abbreviations: SD, standard deviation; CI, confidence interval; STAI, State-Trait Anxiety Inventory.
Table 4 Multivariate effects on outcome variablesa
Effect Value Fb Significance Partial eta squared
Baseline sTAI score (covariate) Pillai trace 0.138 3.435 0.041 0.138
hotelling trace 0.16 3.435 0.041 0.138
Baseline sleep score (covariate) Pillai trace 0.425 15.903 0.000 0.425
hotelling trace 0.74 15.903 0.000 0.425
Treatment group (independent) Pillai trace 0.163 4.199 0.022 0.163
hotelling trace 0.195 4.199 0.022 0.163
study center Pillai trace 0.013 0.292 0.748 0.013
hotelling trace 0.014 0.292 0.748 0.013
Group*center Pillai trace 0.015 0.318 0.729 0.015
hotelling trace 0.015 0.318 0.729 0.015
Notes: aDesign baseline sTAI + baseline sleep + treatment allocation + center + group*center; bexact statistic.
Abbreviation: sTAI, state-Trait Anxiety Inventory.
Table 5 Univariate tests of between-subject effects
Source Dependent variable Type III sum  
of squares
df Mean square F P-value Partial eta   
squared
Model effect on sTAI score  
after treatment
6053.78a 6 1008.963 9.281 0.000 0.559
effect on sleep score  
after treatment
1012.105b 6 168.684 13.424 0.000 0.647
Baseline sTAI score (covariate) effect on sTAI score 440.8265 1 440.827 4.055 0.050 0.084
Baseline sleep score (covariate) effect on sleep score 380.3215 1 380.321 30.266 0.000 0.408
Treatment group effect on sTAI score 593.8728 1 593.873 5.463 0.024 0.110
effect on sleep score 94.32857 1 94.329 7.507 0.009 0.146
study center effect on sTAI score 60.64028 1 60.640 0.558 0.459 0.013
effect on sleep score 0.658766 1 0.659 0.052 0.820 0.001
Group*center effect on sTAI score 6.996249 1 6.996 0.064 0.801 0.001
effect on sleep score 3.32109 1 3.321 0.264 0.610 0.006
error effect on sTAI score 4783.22 44 108.710
effect on sleep score 552.8946 44 12.566
Total effect on sTAI score 10837 50
effect on sleep score 1565 50
Notes: ar2 0.559 (adjusted 0.498); br2 0.647 (adjusted 0.599).
Abbreviation: sTAI, state-Trait Anxiety Inventory.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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In our opinion, alternative medicines, in particular 
products already available as over-the-counter dietary 
supplements, should be subjected to more translational 
research and clinical trials in human subjects, and the results 
made available in the scientific literature. The criteria for 
publishing such studies would need to be different to those 
used with the registration trials for new chemical entities.
Conclusion
In conclusion, L. sativa seed oil was found to be a useful 
sleeping aid and may be a hazard-free line of treatment, 
especially in geriatric patients suffering mild-to-moderate 
forms of anxiety and sleeping difficulties. Larger randomized 
controlled studies are needed to confirm this.
Disclosure
Pharco Pharmaceutical Company, Alexandria, Egypt, 
supported this study by supplying the trial capsules free of 
charge.
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Appendix
Sleeping scale questionnaire
Describe your state during the last week, 
choosing 0 (rare/nil), 1 (sometimes),  
or 2 (often/always)
1.  Did you have difficulty in falling asleep after lying in 
bed?
2.  Did you awaken frequently after falling asleep?
3.  Did you awaken more than once during one night?
4.	 Did you awaken earlier than you should have?
5.	 Did you feel sleepy during the working hours?
	 6.	Did you experience difficulty in concentration during the 
working hours?
	 7.	Did you use or feel badly in need of additional sleeping 
aids?
	 8.	Did you feel clumsy or drowsy after wakening in the 
morning?
	 9.	Did you feel in need of frequent naps or a lie-down during 
the day?
10.	Did you experience comfortable, quiet, and continuous 
sleep?*
*Reversed score